| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,944 |
10,357 |
$597K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
11,127 |
10,523 |
$315K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,612 |
2,440 |
$278K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,093 |
1,945 |
$199K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
4,330 |
4,021 |
$191K |
| 87634 |
|
1,287 |
1,221 |
$102K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,009 |
1,766 |
$95K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,145 |
1,021 |
$58K |
| 71046 |
Radiologic examination, chest; 2 views |
1,953 |
1,802 |
$55K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
676 |
616 |
$36K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
569 |
530 |
$30K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
488 |
475 |
$24K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
305 |
288 |
$12K |
| 74018 |
|
253 |
240 |
$7K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
78 |
75 |
$6K |
| 99382 |
|
77 |
43 |
$2K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
19 |
19 |
$2K |
| 99051 |
|
5,357 |
5,051 |
$2K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
29 |
27 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
114 |
107 |
$1K |
| 99381 |
|
30 |
29 |
$1K |
| 81007 |
|
334 |
319 |
$1K |
| 99383 |
|
47 |
23 |
$902.56 |
| 87807 |
|
74 |
69 |
$820.21 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
16 |
16 |
$667.03 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
26 |
23 |
$288.63 |
| 81003 |
|
121 |
118 |
$238.68 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
366 |
234 |
$151.01 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
29 |
29 |
$140.80 |